Thromb Haemost 2008; 100(06): 1211-1213
DOI: 10.1160/TH08-05-0329
Letters to the Editor
Schattauer GmbH

TUBB1 Q43P polymorphism does not protect against acute coronary syndrome and premature myocardial infarction

Leyre Navarro-Núñez
1   Centro Regional de Hemodonación, University of Murcia, Spain
,
Vanessa Roldán
1   Centro Regional de Hemodonación, University of Murcia, Spain
,
María Luisa Lozano
1   Centro Regional de Hemodonación, University of Murcia, Spain
,
José Rivera
1   Centro Regional de Hemodonación, University of Murcia, Spain
,
Francisco Marin
2   Unit of Cardiology, Virgen de la Arrixaca Hospital, Murcia, Spain
,
Vicente Vicente
1   Centro Regional de Hemodonación, University of Murcia, Spain
,
Constantino Martínez
1   Centro Regional de Hemodonación, University of Murcia, Spain
› Author Affiliations
Financial support: This study was supported by research grant SAF2006–06212 (MCYT and FEDER) and Fondo de Investigación Sanitaria (Red RECAVA RD06/0014/0004). We thank N. García-Barberá for excellent technical cooperation. L.N-N. is a fellow from Ministerio de Educación y Ciencia (BES-2005–7496). CMG is an investigator from Fundación para la Formación e Investigación Sanitarias de la Región de Murcia.
Further Information

Publication History

Received: 27 May 2008

Accepted after major revision: 27 August 2008

Publication Date:
23 November 2017 (online)

 

 
  • References

  • 1 Atherosclerosis Thrombosis, and Vascular Biology Italian Study Group. No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at young age. Circulation 2003; 107: 1117-1122.
  • 2 Shiffman D, O’Meara ES, Bare LA. et al. Association of Gene Variants With Incident Myocardial In- farction in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 2008; 28: 173-179.
  • 3 Jackson SP, Schoenwaelder SM. Antiplatelet therapy: in search of the ‘magic bullet’. Nat Rev Drug Discov 2003; 02: 775-789.
  • 4 Freson K, De Vos R, Wittevrongel C. et al. The TUBB1 Q43P functional polymorphism reduces the risk of cardiovascular disease in men by modulating platelet function and structure. Blood 2005; 106: 2356-2362.
  • 5 Navarro-Nuñez L, Lozano ML, Rivera J. et al. The association of the ß1-tubulin Q43P polymorphism with intracerebral hemorrhage in men. Haematologica 2007; 92: 513-518.
  • 6 Roldán V, Corral J, Marín F. et al. Synergistic association between hypercholesterolemia and the C46T factor XII polymorphism for developing premature myocardial infarction. Thromb Haemost 2005; 94: 1294-1299.
  • 7 Tello-Montoliu A, Marín F, Patel J. et al. plasma angiogenin levels in acute coronary syndromes: implication for prognosis. Eur Heart J 2007; 28: 3006-3011.
  • 8 Miñano A, Ordóñez A, España F. et al. AB0 blood group and risk of venous or arterial thrombosis in carriers of factor V Leiden or prothrombin G20210A polymorphisms. Haematologica 2008; 93: 729-734.
  • 9 Ye Z, Liu EH, Higgins JP. et al. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet 2006; 367: 651-658.
  • 10 Roldan V, Gonzalez-Conejero R, Marin F. et al. Five prothrombotic polymorphisms and the prevalence of premature myocardial infarction. Haematologica 2005; 90: 421-423.
  • 11 Pernod G, Ormezzano O, Vanzetto G. Gene-gene interactions in myocardial infarction. Lancet 2006; 367: 1729-1730.
  • 12 Vokó Z, Bereczky Z, Katona E. et al. Factor XIII Val34Leu variant protects against coronary artery disease. A meta-analysis. Thromb Haemost 2007; 97: 458-463.